Abstract
The SARS-CoV-2 variant of concern Omicron has increased infectivity and immune escape compared with previous variants. Despite a vast majority (∼90%) of the population of Santa Fe city (Argentina) had been vaccinated and/or had been infected by SARS-CoV-2 prior to the arrival of Omicron, the epidemic wave caused by this variant was by far the largest one experienced in the city. Nevertheless, the severity was much lower than that of previous waves. A serosurvey conducted within a month prior to the arrival of Omicron allowed to assess the humoural defences preceding the wave and to evaluate their consequences on infection risk and severity. Santa Fe is a city of 430000 inhabitants, the survey was conducted on 1452 citizens, 514 of which were followed-up until March 2022. A high proportion of the sampled individuals had immunological memory against COVID-19 at the arrival of Omicron (almost 90%), many of whom had high antibody levels. The anti-spike IgG titres were strongly associated with the number of vaccine shots and the vaccine platform received, and also depended markedly on prior COVID-19 diagnosis and the days elapsed since last antigen exposure (vaccine shot or natural infection). In turn, various analytical approaches consistently showed that preceding antibody titres were strongly correlated with COVID-19 incidence and severity of symptoms during the Omicron-dominant wave. Also, receiving a vaccine shot during the wave reduced the COVID-19 risk drastically (15-fold). Here we present real world data showing that COVID-19 incidence and severity during the Omicron-dominant wave was lowest in individuals with high antibody levels, which highlight the importance of maintaining high defences through vaccination in the presence of immune-escaping variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Agencia Santafesina de Ciencia, Tecnnologia e Innovacion (Grant # DEMES-2020-0008).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite de Etica y Seguridad en el Trabajo Experimental del Centro Cientifico Tecnologico CONICET - Santa Fe. APPROVED
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
